Millennium Pharmaceuticals wants to be "the" drug company for the new millennium. Its cancer drug Velcade is approved as a treatment for multiple myeloma (a type of blood cancer) and Mantle Cell Lymphoma (or MCL, an aggressive form of non-Hodgkin's lymphoma). The company has more than a dozen other candidates in the pipeline, most of them cancer-related. Millennium's oncology-focused sales force, in partnership with Johnson & Johnson subsidiary Ortho Biotech, sells the drug in the US; Ortho Biotech is responsible for sales in Europe and in other countries where Velcade is approved (except Japan, which is covered by Janssen). Takeda Pharmaceutical acquired Millennium Pharmaceuticals for $8.8 billion in 2008.

Meridian Bioscience, Inc. company was founded in 1976 and is based in Cincinnati, Ohio. Meridian Bioscience, Inc. operates as an integrated life science company. The company primarily engages in the development, manufacture, sale, and distribution of diagnostic test kits primarily for respiratory, gastrointestinal, viral, and parasitic infectious diseases. Its diagnostic test kits utilize immunodiagnostic technologies, which test samples of blood, urine, stool, and other body fluids or tissues for the presence of antigens and antibodies of specific infectious diseases. The immunodiagnostic technologies include enzyme immunoassay, immunofluorescence, particle agglutination/aggregation, immunodiffusion, complement fixation, and chemical stains. The company also provides transport media that store and preserve specimen samples from patient collection to laboratory testing. In addition, Meridian Bioscience manufactures and distributes bulk antigens, antibodies, and reagents used by researchers and other diagnostic manufacturers. Further, it involves in the contract development and manufacture of proteins and other biologicals for use by biopharmaceutical and biotechnology companies engaged in research for new drugs and vaccines. Meridian Bioscience markets its diagnostic test kits through direct sales force and independent distributors to reference laboratories and hospitals primarily in the United States, Canada, Belgium, France, Holland, Italy, Africa, and the Middle East.

SurModics, Inc. Company was founded in 1979 and is headquartered in Eden Prairie, Minnesota. SurModics, Inc. engages in the development, manufacture, and sale of surface modification and drug delivery technologies to the healthcare industry. The company operates through four business units: Cardiovascular, Ophthalmology, SurModics Pharmaceuticals, and In Vitro Technologies. The Cardiovascular business unit supports the drug delivery and surface modification needs of cardiovascular customers by providing drug delivery polymers and coating technologies, including advanced lubricity (slippery) coatings that ease placement and maneuverability of medical devices in the body. The Ophthalmology business unit develops drug delivery systems for various drugs and other bioactive agents developed by pharmaceutical and ophthalmology companies for the treatment of serious eye diseases.The SurModics Pharmaceuticals business unit specializes in proprietary injectable microparticles and implants based on biodegradable polymers to provide sustained delivery of drugs, as well as supplies biodegradable polymers to corporate and academic customers. The In Vitro Technologies business unit specializes in in vitro diagnostic products and technologies for the biomedical research and medical diagnostic markets. Its products and technologies include protein stabilization reagents, substrates, recombinant autoimmune antigens, surface chemistry technologies for nucleic acid and protein immobilization, and diagnostic format intellectual property. The company markets its technologies and products through sales professionals, as well as sales and marketing relationships with third-parties worldwide. It has collaboration agreements with Genzyme Corporation to develop novel drug delivery solutions with an initial focus on peptide delivery.

ARCA biopharma, Inc. (ARCA), formerly Nuvelo, Inc. is a biopharmaceutical company focused on developing genetically-targeted therapies for heart failure and other cardiovascular diseases. ARCA’s lead product candidate Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator is under review by the United States Food and Drug Administration (FDA), for chronic heart failure (HF). Gencaro is an oral tablet formulation, dosed twice daily. On January 27, 2009, Nuvelo, Inc. (Nuvelo) completed the merger with ARCA biopharma, Inc. (ABI). Pursuant to the Merger, Dawn Acquisition Sub, Inc. merged with and into ABI, with ABI continuing after the merger as the surviving company and a wholly owned subsidiary of Nuvelo. Pursuant to the Merger, ABI changed its name to ARCA biopharma Colorado, Inc. and Nuvelo changed its name to ARCA biopharma, Inc.

Omega Diagnostics Group PLC is a United Kingdom-based holding company. The Company, along with its subsidiaries, is principally engaged in the manufacture, development and distribution of medical diagnostic products. The Company sells a range of products, primarily in the immunoassay, in-vitro diagnostics (IVD) market, through a distribution network in over 100 countries. The Company operates in a niche market in supplying tests for specific infectious diseases, autoimmune disease and food tolerance. The Company subsidiaries include Investment in Omega Diagnostics Limited, Investment in Genesis Diagnostics Limited, Investment in Cambridge Nutritional Sciences Limited, Investment in Bealaw (692) Limited and Investment in Bealaw (693) Limited.

Amerifit Brands aims to calm the irritating tickles, hot flashes, and pains that accompany everyday life. The company develops, markets, and distributes a variety of natural, non-prescription products blended from herbs, minerals, pharmaceuticals, and vitamins. Amerifit's brands include AZO and Estroven (women's wellness), Flex Able (joint health), Sootherbs (cough and cold remedies), and Vitaball (children's multivitamin). Its products take a variety of forms, including lozenges, gumballs, gels, and pills. The company's products are primarily sold in chain drug stores and mass market retailers. Amerifit is owned by private equity firm Charterhouse Group and has agreed to be acquired by Martek Biosciences.

Stallergenes is focused on the development, manufacture, and distribution of immunotherapeutic treatments for food-related and environmental allergies. The company has brought together experts from the fields of biology, botany, and the health community to collaborate on finding ways to deliver relief to people who suffer with problems ranging from asthma to seasonal allergies. These immunotherapy treatments involve conditioning the patient with drugs that introduce pure extracts of the allergen to initiate the body's own natural defenses against it. Wendel Investissement owns about 49% of the company. Stallergenes has research laboratories in Africa, the Americas, Asia, Australia, Europe, and the Middle East.

Amphastar Pharmaceuticals, Inc. is a generic and specialty pharmaceutical company that is engaged in the discovery, development, manufacture and marketing of generic and proprietary pharmaceuticals, innovative delivery systems and active pharmaceutical ingredients. Amphastar’s Management Team takes pride in the Company’s “3H” commitment to "High Quality, High Efficiency and High Technology". In keeping with this pledge of excellence to the consumer, Amphastar will continue to invest in state-of-the-art equipment, research & development, facilities, and the advancement of their employees.

Pharmaxis has an ax to grind with chronic respiratory and autoimmune diseases. The Australian company researches, develops, and markets therapeutic pharmaceutical products to combat these and other illnesses. Pharmaxis has received approval to market asthma treatment Aridol in select regions. The company has research and development programs for additional disease targets such as cystic fibrosis, chronic obstructive pulmonary disease, bronchiectasis, and pulmonary fibrosis. Pharmaxis acquired respiratory therapeutics developer TOPIGEN Pharmaceuticals in 2010, adding to Pharmaxis' roster of potential treatments for respiratory disorders including asthma and COPD.

Janssen has gone totally mental. A US-based arm of Johnson & Johnson'sglobal pharmaceuticals segment, Janssen focuses exclusively on treatments for mental health conditions. Its flagship offering Risperdal combats bipolar mania and schizophrenia, as well as irritability associated with autism. A long-acting injectable version of the drug, called Risperdal Consta, is approved as a treatment for schizophrenia. With its sister company Johnson & Johnson Pharmaceutical Research & Development, the company is working on potential drugs for a range of psychiatric problems, including psychosis, sleep disorders, attention deficit/hyperactivity disorder, depression, and substance abuse.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.